Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib plus temozolomide in IDH-mutant glioma
NL-OMON60513Phase 2Active, not recruiting
- Sponsor
- Servier
- Start
- Apr 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vorasidenib and temozolomide in glioma, astrocytoma and Oligodendroglioma (OG) (2 arms), sponsored by Servier. Primary endpoints: Dose-limiting toxicities, Incidence and severity of adverse events, serious adverse events, and adverse events of special interest and 1 more. Started Apr 2025; status: active, not recruiting.
02
Drugs
vorasidenibtemozolomide
03
Conditions
gliomaastrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on NL-OMON60513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60513.